DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Procedure: haploidentical stem cell transplant
Drug: Filgrastim
Drug: Sirolimus
Drug: Alemtuzumab
Drug: Pentostatin
Drug: Cyclophosphamide
Drug: Hydroxyurea

First Posted Date: 2017-03-13

Last Posted Date: 2024-08-07

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 57

Registration Number: NCT03077542

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pathophysiology of Acute Pain in Patients With Sickle Cell Disease

Completed

Conditions: Sickle Cell Disease

First Posted Date: 2017-02-10

Last Posted Date: 2025-05-06

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 99

Registration Number: NCT03049475

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults

Phase 2

Completed

Conditions: Proteomics
Lipoprotein Metabolism
PCSK9

Interventions: Drug: control fish oil
Drug: LCMUFA-rich saury oil

First Posted Date: 2017-02-06

Last Posted Date: 2020-08-12

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 37

Registration Number: NCT03043365

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation

Not Applicable

Completed

Conditions: Mitral Valve Failure

Interventions: Device: Edwards SAPIEN 3 transcatheter heart valve
Device: ASHI INTECC Astato XS 20

First Posted Date: 2017-01-09

Last Posted Date: 2023-08-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 32

Registration Number: NCT03015194

Locations: 🇺🇸
Carilion Medical Center, Roanoke, Virginia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Medstar Washington Hospital Center, Cardiovascular Research Program, Washington, District of Columbia, United States

and more 3 locations

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Relapsed Acute Myeloid Leukemia

Interventions: Drug: Pembrolizumab
Drug: Decitabine

First Posted Date: 2016-12-19

Last Posted Date: 2022-12-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 10

Registration Number: NCT02996474

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Lung Tissue Research Consortium

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Interstitial Lung Disease

Interventions: Procedure: Lung biopsy/lobectomy

First Posted Date: 2016-12-09

Last Posted Date: 2019-03-08

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 247

Registration Number: NCT02988388

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸
Temple University, Philadelphia, Pennsylvania, United States

and more 1 locations

Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Phase 2

Active, not recruiting

Conditions: Severe Aplastic Anemia

Interventions: Drug: Sirolimus

First Posted Date: 2016-12-02

Last Posted Date: 2025-05-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 83

Registration Number: NCT02979873

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Impact of Elastin Mediated Vascular Stiffness on End Organs

Recruiting

Conditions: Cardiovascular Disease
Supravalvular Aortic Stenosis
Williams Syndrome

First Posted Date: 2016-07-21

Last Posted Date: 2025-05-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 218

Registration Number: NCT02840448

Locations: 🇺🇸
Washington University School of medicine, Saint Louis, Missouri, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

CADASIL Disease Discovery

Completed

Conditions: Cardiovascular Disease
Pathogenesis of CADASIL
Germline Mutation in the NOTCH 3 Gene
Arterial Stiffness
Clinical Phenotype of CADASIL

First Posted Date: 2016-07-04

Last Posted Date: 2025-04-11

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 20

Registration Number: NCT02821780

Locations: 🇺🇸
Nationwide Children s Hospital, Columbus, Ohio, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

Not Applicable

Completed

Conditions: Coronary Artery Disease
Atherosclerosis
Diabetes

Interventions: Dietary Supplement: Nicotinamide riboside (NR)
Drug: Placebo

First Posted Date: 2016-06-24

Last Posted Date: 2019-09-17

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 38

Registration Number: NCT02812238

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy